Company will offer first public demonstration of its AVATAR Foundry technology and enroll new participants in its beta access program
Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, today announced its speaker lineup and activities for the upcoming ISCT 2024, the annual meeting of the International Society for Cell & Gene Therapy, taking place May 29 – June 1 in Vancouver, British Columbia. Along with AmplifyBio and the University of Virginia, Xcellbio will offer poster presentations of its AVATAR technology in T cell manufacturing and analytical applications.
“ISCT is the leading organization dedicated to cell and gene therapies, and we look forward to this conference every year to meet with customers, collaborators, and anyone else whose cell therapy development efforts can be accelerated by our unique approach to conditioning cells for more potent and persistent cancer-killing abilities,” said Brian Feth, co-founder and CEO at Xcellbio.
Building upon the success of the AVATAR system previously launched for cell and gene therapy research and development, the cGMP AVATAR Foundry system represents the latest platform advancement to deliver novel capabilities for improving expansion and potency of cell therapies. The AVATAR product family now covers small-scale research and process development capabilities, as well as scale-up bioreactor manufacturing platforms for metabolically reprogramming therapeutic cells to improve their expansion, potency, and persistence in the tumor microenvironment.
Booth Activities
Xcellbio can be found at booth #704 in the ISCT exhibit hall. Conference attendees may visit the booth to see the AVATAR Foundry system and experience a live demonstration of the instrument. In addition, information about participating in the expanded beta access program for the AVATAR Foundry system will be available.
Poster Presentations
The following posters will include data generated with the AVATAR system:
Poster #933: Adapting T cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency
Presenter: Craig Fett, AmplifyBio
Poster #1009: Acclimation of Effector T Cells to Tumor Microenvironment Induces Enhanced Proliferation and Anti-tumor Activity Against Breast Cancer Cell Lines
Presenter: Archana Thakur, University of Virginia
Poster #912: Modulating Environmental Conditions to Enhance Production of Potent Cell Therapies for the Solid Tumor Microenvironment
Presenter: Yelena Bronevetsky, Hadia Lemar, Evan Massi, Candy Garcia, Xcellbio
More information about the beta access program is available at https://www.xcellbio.com/gmp.
About Xcell Biosciences
Xcellbio is driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company’s commercial instruments and software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cGMP cell therapy manufacturing platform. Based in San Francisco, Xcellbio can also be found online at www.xcellbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522648577/en/
Contacts
For Xcellbio
Suzanne Howard
suzanne@bioscribe.com
